Literature DB >> 15919000

Renal urate handling: clinical relevance of recent advances.

Naohiko Anzai1, Atsushi Enomoto, Hitoshi Endou.   

Abstract

Urate is the major inert end product of purine degradation in higher primates in contrast to most other mammals because of the genetic silencing of hepatic oxidative enzyme uricase. The kidney plays a dominant role in urate elimination. The kidney excretes 70% of the daily urate production. Therefore, it is important to understand renal urate handling mechanism because the under excretion of urate has been implicated in the development of hyperuricemia that leads to gout. The urate transport systems exist in the proximal tubule but they are complicated because of their bidirectional transport and the species differences. Recently, we have identified the urate-anion exchanger URAT1 (SLC22A12) in the human kidney and found that defects in SLC22A12 lead to idiopathic renal hypouricemia. URAT1 is targeted by uricosuric and antiuricosuric agents that affect urate excretion. Molecular identification of urate transporting proteins will lead to the new drug development for hyperuricemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919000     DOI: 10.1007/s11926-996-0044-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  44 in total

Review 1.  Making protein interactions druggable: targeting PDZ domains.

Authors:  Kumlesh K Dev
Journal:  Nat Rev Drug Discov       Date:  2004-12       Impact factor: 84.694

2.  Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains.

Authors:  O Kocher; N Comella; K Tognazzi; L F Brown
Journal:  Lab Invest       Date:  1998-01       Impact factor: 5.662

3.  Patients with renal hypouricemia with exercise-induced acute renal failure and chronic renal dysfunction.

Authors:  Y Kikuchi; H Koga; Y Yasutomo; Y Kawabata; E Shimizu; M Naruse; S Kiyama; H Nonoguchi; K Tomita; Y Sasatomi; S Takebayashi
Journal:  Clin Nephrol       Date:  2000-06       Impact factor: 0.975

4.  Recurrence of acute renal failure and renal hypouricaemia.

Authors:  T Murakami; H Kawakami; M Fukuda; H Shiigi
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

5.  Two male siblings with hereditary renal hypouricemia and exercise-induced ARF.

Authors:  Motoko Tanaka; Kazuko Itoh; Kazunori Matsushita; Kazutaka Matsushita; Naoki Wakita; Masataka Adachi; Hiroshi Nonoguchi; Kenichiro Kitamura; Makoto Hosoyamada; Hitoshi Endou; Kimio Tomita
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

6.  Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule.

Authors:  Promsuk Jutabha; Yoshikatsu Kanai; Makoto Hosoyamada; Arthit Chairoungdua; Do Kyung Kim; Yuji Iribe; Ellappan Babu; Ju Young Kim; Naohiko Anzai; Varanuj Chatsudthipong; Hitoshi Endou
Journal:  J Biol Chem       Date:  2003-05-10       Impact factor: 5.157

Review 7.  Uric acid transport.

Authors:  Mohammed A Rafey; Michael S Lipkowitz; Edgar Leal-Pinto; Ruth G Abramson
Journal:  Curr Opin Nephrol Hypertens       Date:  2003-09       Impact factor: 2.894

8.  Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux.

Authors:  Adiya Bakhiya; Andrew Bahn; Gerhard Burckhardt; Natascha Wolff
Journal:  Cell Physiol Biochem       Date:  2003

9.  Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules.

Authors:  Sophapun Ekaratanawong; Naohiko Anzai; Promsuk Jutabha; Hiroki Miyazaki; Rie Noshiro; Michio Takeda; Yoshikatsu Kanai; Samaisukh Sophasan; Hitoshi Endou
Journal:  J Pharmacol Sci       Date:  2004-03       Impact factor: 3.337

10.  Renal hypouricemia due to an isolated renal defect of urate transport.

Authors:  I Hisatome; K Ogino; M Saito; J Miyamoto; J Hasegawa; H Kotake; H Mashiba; S Nakamoto
Journal:  Nephron       Date:  1988       Impact factor: 2.847

View more
  15 in total

1.  Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.

Authors:  Guohua An; Wei Liu; W Rachel Duan; Wolfram Nothaft; Walid Awni; Sandeep Dutta
Journal:  AAPS J       Date:  2015-01-08       Impact factor: 4.009

2.  Analyses of 5' regulatory region polymorphisms in human SLC22A6 (OAT1) and SLC22A8 (OAT3).

Authors:  Vibha Bhatnagar; Gang Xu; Bruce A Hamilton; David M Truong; Satish A Eraly; Wei Wu; Sanjay K Nigam
Journal:  J Hum Genet       Date:  2006-04-29       Impact factor: 3.172

Review 3.  Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies.

Authors:  Naohiko Anzai; Promsuk Jutabha; Sirirat Amonpatumrat-Takahashi; Hiroyuki Sakurai
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

4.  Hyperuricemia and gout caused by missense mutation in d-lactate dehydrogenase.

Authors:  Max Drabkin; Yuval Yogev; Lior Zeller; Raz Zarivach; Ran Zalk; Daniel Halperin; Ohad Wormser; Evgenia Gurevich; Daniel Landau; Rotem Kadir; Yonatan Perez; Ohad S Birk
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

Review 5.  Cardiovascular Safety of Urate Lowering Therapies.

Authors:  Eun Ha Kang; Seoyoung C Kim
Journal:  Curr Rheumatol Rep       Date:  2019-07-24       Impact factor: 4.592

Review 6.  New developments in clinically relevant mechanisms and treatment of hyperuricemia.

Authors:  Susan J Lee; Robert A Terkeltaub
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

7.  [Molecular basis of primary renal hyperuricemia : role of the human urate transporter hURAT1].

Authors:  S Unger; A-K Tausche; S Kopprasch; S R Bornstein; M Aringer; J Grässler
Journal:  Z Rheumatol       Date:  2007-11       Impact factor: 1.372

8.  Uric Acid nephrolithiasis: recent progress and future directions.

Authors:  Tin C Ngo; Dean G Assimos
Journal:  Rev Urol       Date:  2007

9.  Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Authors:  Sophie L Stocker; Kenneth M Williams; Andrew J McLachlan; Garry G Graham; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 10.  Gender differences in kidney function.

Authors:  Ivan Sabolić; Abdul R Asif; Wolfgang E Budach; Christoph Wanke; Andrew Bahn; Gerhard Burckhardt
Journal:  Pflugers Arch       Date:  2007-07-19       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.